NO20083030L - 1-Orthofluorfenyl-substituert 1,2,5-tiazolidindionderivater som PTP-AS inhibitorer - Google Patents
1-Orthofluorfenyl-substituert 1,2,5-tiazolidindionderivater som PTP-AS inhibitorerInfo
- Publication number
- NO20083030L NO20083030L NO20083030A NO20083030A NO20083030L NO 20083030 L NO20083030 L NO 20083030L NO 20083030 A NO20083030 A NO 20083030A NO 20083030 A NO20083030 A NO 20083030A NO 20083030 L NO20083030 L NO 20083030L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- inhibitors
- formula
- treatment
- insulin resistance
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 150000001474 2,5-thiazolidinediones Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 abstract 3
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 abstract 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 3
- 206010022489 Insulin Resistance Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 102000014400 SH2 domains Human genes 0.000 abstract 1
- 108050003452 SH2 domains Proteins 0.000 abstract 1
- 210000001789 adipocyte Anatomy 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 208000023589 ischemic disease Diseases 0.000 abstract 1
- 206010024627 liposarcoma Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
Forbindelser med formel (I) er inhibitorer av proteintyrosinfosfataser (PTPaser) og kan således anvendes for behandlingen av tilstander mediert av PTPase aktivitet. Forbindelsene ifølge oppfinnelsen kan også anvendes som inhibitorer av andre enzymer kjennetegnet ved en fosfotyrosinbindingsregion slik som SH2 domenet. Følgelig kan forbindelsene med formel (I) anvendes for hindring og/eller behandling av insulinresistens assosiert med fedme, glukoseintoleranse, diabetes mellitus, hypertensjon og iskemiske sykdommer i store og små blodkar, tilstander som ledsager type-2 diabetes, inkludert hyperlipidemi, hypertriglyceridemi, aterosklerose, vaskulær restenose, irritabelt tarmsyndrom, pankreatitt, adiposecelletumorer og karsinomer slike som liposarkom, dyslipidemi og andre forstyrrelser hvor insulinresistens er indikert. I tillegg kan forbindelsene ifølge oppfinnelsen anvendes for behandling og/eller hindring av cancer, osteoporose, neurodegenerative og infeksjonssykdommer og sykdommer som involverer inflammasjon og immunsystemet.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74849205P | 2005-12-08 | 2005-12-08 | |
PCT/US2006/046542 WO2007067612A1 (en) | 2005-12-08 | 2006-12-06 | 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20083030L true NO20083030L (no) | 2008-08-28 |
Family
ID=37903424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20083030A NO20083030L (no) | 2005-12-08 | 2008-07-04 | 1-Orthofluorfenyl-substituert 1,2,5-tiazolidindionderivater som PTP-AS inhibitorer |
Country Status (23)
Country | Link |
---|---|
US (1) | US8252820B2 (no) |
EP (1) | EP1963293A1 (no) |
JP (1) | JP2009518419A (no) |
KR (1) | KR20080075218A (no) |
CN (1) | CN101336235A (no) |
AR (1) | AR058285A1 (no) |
AU (1) | AU2006321902B2 (no) |
BR (1) | BRPI0619567A2 (no) |
CA (1) | CA2631007A1 (no) |
CR (1) | CR10047A (no) |
EC (1) | ECSP088509A (no) |
GT (1) | GT200800093A (no) |
IL (1) | IL191711A0 (no) |
MA (1) | MA30018B1 (no) |
NO (1) | NO20083030L (no) |
NZ (1) | NZ568663A (no) |
PE (2) | PE20100470A1 (no) |
RU (1) | RU2008127262A (no) |
TN (1) | TNSN08248A1 (no) |
TW (1) | TW200800928A (no) |
UA (1) | UA94921C2 (no) |
WO (1) | WO2007067612A1 (no) |
ZA (1) | ZA200804489B (no) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080293782A1 (en) * | 2005-12-08 | 2008-11-27 | David Barnes | 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors |
KR20080074970A (ko) * | 2005-12-08 | 2008-08-13 | 노파르티스 아게 | 단백질 티로신 포스파타제 (ptpase)에 의해 매개되는질병의 치료에 유용한 1,2,5-티아졸리딘 유도체 |
BRPI0710182A2 (pt) * | 2006-03-31 | 2012-08-07 | Novartis Ag | compostos orgÂnicos. |
DE102007015169A1 (de) * | 2007-03-27 | 2008-10-02 | Universität des Saarlandes Campus Saarbrücken | 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US20130109887A1 (en) * | 2010-08-26 | 2013-05-02 | Albermarle Corporation | Processes for producing 1-bromo-2- (cyclopropyl methoxy)-5-fluoro-4-methoxybenzene |
US9040525B2 (en) | 2010-10-08 | 2015-05-26 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
JPWO2012147516A1 (ja) | 2011-04-28 | 2014-07-28 | 持田製薬株式会社 | 環状アミド誘導体 |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2017078499A2 (ko) * | 2015-11-06 | 2017-05-11 | 경북대학교 산학협력단 | 단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물 |
PE20210372A1 (es) * | 2018-06-21 | 2021-02-26 | Abbvie Inc | Inhibidores de proteina tirosina fosfatasa y sus metodos de uso |
MX2021003240A (es) | 2018-09-18 | 2021-05-12 | Basf Se | Compuestos de diaminotriazina. |
AU2020234712A1 (en) * | 2019-03-14 | 2021-09-09 | Abbvie Inc. | Protein tyrosine phosphatase inhibitors and methods of use thereof |
EP4077291A1 (en) * | 2019-12-18 | 2022-10-26 | Calico Life Sciences LLC | Protein tyrosine phosphatase inhibitors and methods of use thereof |
WO2021127586A1 (en) * | 2019-12-20 | 2021-06-24 | Calico Life Sciences Llc | Protein tyrosine phosphatase degraders and methods of use thereof |
EP4211122A1 (en) * | 2020-09-11 | 2023-07-19 | Calico Life Sciences LLC | Protein tyrosine phosphatase inhibitors and methods of use thereof |
EP4284786A1 (en) | 2021-01-27 | 2023-12-06 | Basf Se | Diaminotriazine compounds |
JP2024509962A (ja) * | 2021-03-11 | 2024-03-05 | カムクワット バイオサイエンシーズ インコーポレイテッド | 複素環及びその使用 |
CA3236854A1 (en) * | 2021-11-11 | 2023-05-19 | Andrew Bogdan | Protein tyrosine phosphatase inhibitors and methods of use thereof |
CA3236853A1 (en) * | 2021-11-11 | 2023-05-19 | Andrew Bogdan | Protein tyrosine phosphatase inhibitors and methods of use thereof |
WO2023147531A1 (en) * | 2022-01-31 | 2023-08-03 | Bristol-Myers Squibb Company | Inhibitors of protein tyrosine phosphatase, compositions, and methods of use |
TW202337459A (zh) * | 2022-02-02 | 2023-10-01 | 美商耐瑞歐醫療公司 | 蛋白酪胺酸磷酸酶抑制劑及其用途 |
WO2023150150A1 (en) * | 2022-02-02 | 2023-08-10 | Nerio Therapeutics, Inc. | Protein tyrosine phosphatase inhibitors and uses thereof |
WO2023150523A1 (en) * | 2022-02-02 | 2023-08-10 | Nerio Therapeutics, Inc. | Protein tyrosine phosphatase inhibitors and uses thereof |
WO2024059041A1 (en) * | 2022-09-13 | 2024-03-21 | Kumquat Biosciences, Inc. | Benzo-fused n-heterocycles and uses thereof |
WO2024067802A1 (zh) * | 2022-09-30 | 2024-04-04 | 深圳众格生物科技有限公司 | 蛋白酪氨酸磷酸酶抑制剂及其制备方法和医药用途 |
WO2024102794A1 (en) * | 2022-11-09 | 2024-05-16 | Bristol-Myers Squibb Company | Inhibitors of protein tyrosine phosphatase, compositions, and methods of use |
WO2024137727A1 (en) * | 2022-12-21 | 2024-06-27 | Bristol-Myers Squibb Company | 1,2,4-thiazolidin-3-one-1,1-dioxide inhibitors of protein tyrosine phosphatase, compositions, and methods of use |
WO2024141015A1 (en) * | 2022-12-30 | 2024-07-04 | Insilico Medicine Ip Limited | Protein tyrosine phosphatase inhibitors and uses thereof |
CN117343052B (zh) * | 2023-12-04 | 2024-02-06 | 英矽智能科技(上海)有限公司 | 蛋白酪氨酸磷酸酶抑制剂及其应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002254342A1 (en) * | 2001-03-23 | 2002-10-08 | The Board Of Trustees Of The University Of Illinois | Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same |
PL372848A1 (en) * | 2002-04-03 | 2005-08-08 | Novartis Ag | 5-substituted 1,1-dioxo-[1,2,5]thiazolidine-3-one derivatives as ptpase 1b inhibitors |
GB0225986D0 (en) * | 2002-11-07 | 2002-12-11 | Astrazeneca Ab | Chemical compounds |
GB0227813D0 (en) * | 2002-11-29 | 2003-01-08 | Astrazeneca Ab | Chemical compounds |
EP1594497B1 (en) * | 2002-12-30 | 2009-05-27 | Vertex Pharmaceuticals Incorporated | Sulfhydantoins as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
US7141596B2 (en) * | 2003-10-08 | 2006-11-28 | Incyte Corporation | Inhibitors of proteins that bind phosphorylated molecules |
US20080293782A1 (en) | 2005-12-08 | 2008-11-27 | David Barnes | 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors |
UA94724C2 (en) * | 2005-12-08 | 2011-06-10 | Новартис Аг | Thiadiazolidinone derivatives as antidiabetic agents |
KR20080074970A (ko) | 2005-12-08 | 2008-08-13 | 노파르티스 아게 | 단백질 티로신 포스파타제 (ptpase)에 의해 매개되는질병의 치료에 유용한 1,2,5-티아졸리딘 유도체 |
BRPI0710182A2 (pt) | 2006-03-31 | 2012-08-07 | Novartis Ag | compostos orgÂnicos. |
-
2006
- 2006-06-12 UA UAA200807752A patent/UA94921C2/ru unknown
- 2006-12-06 PE PE2010000301A patent/PE20100470A1/es not_active Application Discontinuation
- 2006-12-06 RU RU2008127262/04A patent/RU2008127262A/ru not_active Application Discontinuation
- 2006-12-06 EP EP06844889A patent/EP1963293A1/en not_active Withdrawn
- 2006-12-06 NZ NZ568663A patent/NZ568663A/en not_active IP Right Cessation
- 2006-12-06 JP JP2008544464A patent/JP2009518419A/ja active Pending
- 2006-12-06 AR ARP060105391A patent/AR058285A1/es not_active Application Discontinuation
- 2006-12-06 WO PCT/US2006/046542 patent/WO2007067612A1/en active Application Filing
- 2006-12-06 PE PE2006001572A patent/PE20071094A1/es not_active Application Discontinuation
- 2006-12-06 CA CA002631007A patent/CA2631007A1/en not_active Abandoned
- 2006-12-06 AU AU2006321902A patent/AU2006321902B2/en not_active Ceased
- 2006-12-06 BR BRPI0619567-9A patent/BRPI0619567A2/pt not_active IP Right Cessation
- 2006-12-06 KR KR1020087016433A patent/KR20080075218A/ko not_active Application Discontinuation
- 2006-12-06 CN CNA2006800524439A patent/CN101336235A/zh active Pending
- 2006-12-06 US US12/096,432 patent/US8252820B2/en not_active Expired - Fee Related
- 2006-12-07 TW TW095145872A patent/TW200800928A/zh unknown
-
2008
- 2008-05-26 IL IL191711A patent/IL191711A0/en unknown
- 2008-05-27 ZA ZA200804489A patent/ZA200804489B/xx unknown
- 2008-06-02 MA MA30986A patent/MA30018B1/fr unknown
- 2008-06-05 CR CR10047A patent/CR10047A/es not_active Application Discontinuation
- 2008-06-06 GT GT200800093A patent/GT200800093A/es unknown
- 2008-06-06 TN TNP2008000248A patent/TNSN08248A1/en unknown
- 2008-06-06 EC EC2008008509A patent/ECSP088509A/es unknown
- 2008-07-04 NO NO20083030A patent/NO20083030L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
RU2008127262A (ru) | 2010-01-20 |
WO2007067612A1 (en) | 2007-06-14 |
ECSP088509A (es) | 2008-07-30 |
CR10047A (es) | 2008-10-16 |
IL191711A0 (en) | 2008-12-29 |
EP1963293A1 (en) | 2008-09-03 |
AR058285A1 (es) | 2008-01-30 |
US8252820B2 (en) | 2012-08-28 |
ZA200804489B (en) | 2009-08-26 |
GT200800093A (es) | 2010-07-09 |
BRPI0619567A2 (pt) | 2011-10-04 |
TW200800928A (en) | 2008-01-01 |
PE20071094A1 (es) | 2008-01-07 |
AU2006321902B2 (en) | 2011-11-10 |
KR20080075218A (ko) | 2008-08-14 |
MA30018B1 (fr) | 2008-12-01 |
PE20100470A1 (es) | 2010-07-13 |
TNSN08248A1 (en) | 2009-10-30 |
NZ568663A (en) | 2011-07-29 |
CA2631007A1 (en) | 2007-06-14 |
JP2009518419A (ja) | 2009-05-07 |
UA94921C2 (en) | 2011-06-25 |
CN101336235A (zh) | 2008-12-31 |
US20100035942A1 (en) | 2010-02-11 |
AU2006321902A1 (en) | 2007-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20083030L (no) | 1-Orthofluorfenyl-substituert 1,2,5-tiazolidindionderivater som PTP-AS inhibitorer | |
NO20083031L (no) | Tiadiazolderivater som anti-diabetiske agenter | |
TNSN08247A1 (en) | 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors | |
WO2007115058A3 (en) | Thiadiazolidinone inhibitors of ptpase | |
NO20044745L (no) | 5-substituerte 1,1-diokso-1,2,5-tiazolidin-3-on-derivater som PTPASE 1B inhibitorer | |
Cameron et al. | Discovery and preclinical characterization of 6-chloro-5-[4-(1-hydroxycyclobutyl) phenyl]-1 H-indole-3-carboxylic acid (PF-06409577), a direct activator of adenosine monophosphate-activated protein kinase (AMPK), for the potential treatment of diabetic nephropathy | |
AR066820A1 (es) | Compuestos de tiadiazolidin-3 ona | |
Mellini et al. | Sirtuin modulators: an updated patent review (2012–2014) | |
WO2007070434A3 (en) | Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes | |
Rotili et al. | Identification of tri‐and tetracyclic pyrimidinediones as sirtuin inhibitors | |
GEP20135724B (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes | |
TNSN08367A1 (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
WO2010074588A3 (en) | Pharmaceutical compounds | |
NO20091700L (no) | Florizinanaloger som inhibitorer av glukose-ko-transporter 2 | |
BRPI0606704A (pt) | derivados de piridinila e pirimidinila substituìdos como moduladores do metabolismo e o tratamento de distúrbios relacionados ao mesmo | |
WO2008033562A3 (en) | Kinase inhibitor compounds | |
WO2007149451A3 (en) | Cycloalkanopyrrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors | |
WO2006058064A3 (en) | Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
WO2007071766A3 (en) | Phenoxy acetic acids as ppar delta activators | |
EA201270215A1 (ru) | Apaf-1 ингибиторные соединения | |
NO20075731L (no) | Inhibitorer av mikrosomalt triglyceridtransferprotein og APO-B-sekresjon | |
WO2006130613A3 (en) | Substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases | |
WO2008046082A3 (en) | Use of heterocyclic compounds as therapeutic agents | |
Mellini et al. | Identification of diketopiperazine-containing 2-anilinobenzamides as potent sirtuin 2 (SIRT2)-Selective inhibitors targeting the “selectivity pocket”, substrate-binding site, and NAD+-Binding site | |
Zhao et al. | Post-translational modifications of nuclear sirtuins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |